BR112022009018A2 - Biomarcadores para composições de nanopartícula - Google Patents
Biomarcadores para composições de nanopartículaInfo
- Publication number
- BR112022009018A2 BR112022009018A2 BR112022009018A BR112022009018A BR112022009018A2 BR 112022009018 A2 BR112022009018 A2 BR 112022009018A2 BR 112022009018 A BR112022009018 A BR 112022009018A BR 112022009018 A BR112022009018 A BR 112022009018A BR 112022009018 A2 BR112022009018 A2 BR 112022009018A2
- Authority
- BR
- Brazil
- Prior art keywords
- biomarkers
- compositions
- rbi
- nanoparticles
- nanoparticle compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 239000002105 nanoparticle Substances 0.000 title abstract 3
- 239000000090 biomarker Substances 0.000 title abstract 2
- 101001003194 Eleusine coracana Alpha-amylase/trypsin inhibitor Proteins 0.000 abstract 2
- 101150020330 ATRX gene Proteins 0.000 abstract 1
- 102100027211 Albumin Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 108700020462 BRCA2 Proteins 0.000 abstract 1
- 102000052609 BRCA2 Human genes 0.000 abstract 1
- 101150008921 Brca2 gene Proteins 0.000 abstract 1
- 102100029758 Cadherin-4 Human genes 0.000 abstract 1
- 101100002344 Caenorhabditis elegans arid-1 gene Proteins 0.000 abstract 1
- 108010078791 Carrier Proteins Proteins 0.000 abstract 1
- 102000014914 Carrier Proteins Human genes 0.000 abstract 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 abstract 1
- 108010009367 Cyclin-Dependent Kinase Inhibitor p18 Proteins 0.000 abstract 1
- 102000009503 Cyclin-Dependent Kinase Inhibitor p18 Human genes 0.000 abstract 1
- 101150077031 DAXX gene Proteins 0.000 abstract 1
- 102100028559 Death domain-associated protein 6 Human genes 0.000 abstract 1
- 102100032610 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Human genes 0.000 abstract 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 abstract 1
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 abstract 1
- 101000794580 Homo sapiens Cadherin-4 Proteins 0.000 abstract 1
- 101001095815 Homo sapiens E3 ubiquitin-protein ligase RING2 Proteins 0.000 abstract 1
- 101001014590 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas Proteins 0.000 abstract 1
- 101001014594 Homo sapiens Guanine nucleotide-binding protein G(s) subunit alpha isoforms short Proteins 0.000 abstract 1
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 abstract 1
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 abstract 1
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 abstract 1
- 101001025967 Homo sapiens Lysine-specific demethylase 6A Proteins 0.000 abstract 1
- 101001057193 Homo sapiens Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Proteins 0.000 abstract 1
- 101001014610 Homo sapiens Neuroendocrine secretory protein 55 Proteins 0.000 abstract 1
- 101000797903 Homo sapiens Protein ALEX Proteins 0.000 abstract 1
- 101000655119 Homo sapiens T-cell leukemia homeobox protein 3 Proteins 0.000 abstract 1
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 abstract 1
- 101000740048 Homo sapiens Ubiquitin carboxyl-terminal hydrolase BAP1 Proteins 0.000 abstract 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 abstract 1
- 101000759453 Homo sapiens YY1-associated protein 1 Proteins 0.000 abstract 1
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 abstract 1
- 101000740049 Latilactobacillus curvatus Bioactive peptide 1 Proteins 0.000 abstract 1
- 102100037462 Lysine-specific demethylase 6A Human genes 0.000 abstract 1
- 102100027240 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 Human genes 0.000 abstract 1
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 abstract 1
- 102000008071 Mismatch Repair Endonuclease PMS2 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 abstract 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 abstract 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 abstract 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 abstract 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 abstract 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 abstract 1
- 102100032568 T-cell leukemia homeobox protein 3 Human genes 0.000 abstract 1
- 102100031027 Transcription activator BRG1 Human genes 0.000 abstract 1
- 102100023931 Transcriptional regulator ATRX Human genes 0.000 abstract 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 abstract 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 abstract 1
- 108700042462 X-linked Nuclear Proteins 0.000 abstract 1
- 102100023267 YY1-associated protein 1 Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940124302 mTOR inhibitor Drugs 0.000 abstract 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nanotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Crystallography & Structural Chemistry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962933820P | 2019-11-11 | 2019-11-11 | |
| US202062991469P | 2020-03-18 | 2020-03-18 | |
| PCT/US2020/060070 WO2021096997A1 (en) | 2019-11-11 | 2020-11-11 | Biomarkers for nanoparticle compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022009018A2 true BR112022009018A2 (pt) | 2022-10-11 |
Family
ID=75846208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022009018A BR112022009018A2 (pt) | 2019-11-11 | 2020-11-11 | Biomarcadores para composições de nanopartícula |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20230000844A1 (https=) |
| EP (1) | EP4058000A4 (https=) |
| JP (1) | JP2023500391A (https=) |
| KR (1) | KR20220113699A (https=) |
| CN (1) | CN114945358A (https=) |
| AU (1) | AU2020382817A1 (https=) |
| BR (1) | BR112022009018A2 (https=) |
| CA (1) | CA3161105A1 (https=) |
| IL (1) | IL292859A (https=) |
| MX (1) | MX2022005715A (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| ES3009356T3 (en) | 2015-06-29 | 2025-03-26 | Abraxis Bioscience Llc | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
| IL277402B1 (en) | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin |
| BR112022007710A2 (pt) | 2019-10-28 | 2022-07-12 | Abraxis Bioscience Llc | Composições farmacêuticas de albumina e rapamicina |
| WO2024228964A1 (en) * | 2023-04-30 | 2024-11-07 | Aadi Bioscience, Inc. | Treatments comprising an mtor inhibitor nanoparticle composition |
| WO2025129108A1 (en) | 2023-12-14 | 2025-06-19 | Aadi Bioscience, Inc. | Methods of treating a cancer in an individual |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2131821B1 (en) * | 2007-03-07 | 2018-05-09 | Abraxis BioScience, LLC | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| US20140186447A1 (en) * | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| WO2015170248A1 (en) * | 2014-05-05 | 2015-11-12 | Cellworks Research India Pvt. Ltd. | Combination of nelfinavir, metformin and rosuvastatin for treating cancer caused by aberrations in pten/tp53 |
| ES3009356T3 (en) * | 2015-06-29 | 2025-03-26 | Abraxis Bioscience Llc | Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors |
| JP2018521058A (ja) * | 2015-06-29 | 2018-08-02 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して固形腫瘍を処置する方法 |
| KR20240144442A (ko) * | 2015-06-29 | 2024-10-02 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물에 대한 바이오마커 |
| EP3727368A4 (en) * | 2017-12-19 | 2021-10-20 | Abraxis BioScience, LLC | METHOD OF TREATMENT IN COLON CANCER WITH NANOPARTICLE MTOR INHIBITOR COMBINATION THERAPY |
-
2020
- 2020-11-11 EP EP20887933.8A patent/EP4058000A4/en active Pending
- 2020-11-11 AU AU2020382817A patent/AU2020382817A1/en not_active Abandoned
- 2020-11-11 JP JP2022526822A patent/JP2023500391A/ja active Pending
- 2020-11-11 US US17/775,562 patent/US20230000844A1/en not_active Abandoned
- 2020-11-11 IL IL292859A patent/IL292859A/en unknown
- 2020-11-11 KR KR1020227019284A patent/KR20220113699A/ko active Pending
- 2020-11-11 MX MX2022005715A patent/MX2022005715A/es unknown
- 2020-11-11 CA CA3161105A patent/CA3161105A1/en active Pending
- 2020-11-11 BR BR112022009018A patent/BR112022009018A2/pt unknown
- 2020-11-11 CN CN202080092690.1A patent/CN114945358A/zh active Pending
- 2020-12-02 US US17/110,133 patent/US20210137848A1/en not_active Abandoned
-
2022
- 2022-12-19 US US18/084,411 patent/US20230293449A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL292859A (en) | 2022-07-01 |
| JP2023500391A (ja) | 2023-01-05 |
| US20210137848A1 (en) | 2021-05-13 |
| AU2020382817A1 (en) | 2022-06-16 |
| US20230000844A1 (en) | 2023-01-05 |
| EP4058000A4 (en) | 2024-02-28 |
| CN114945358A (zh) | 2022-08-26 |
| KR20220113699A (ko) | 2022-08-16 |
| CA3161105A1 (en) | 2021-05-20 |
| US20230293449A1 (en) | 2023-09-21 |
| EP4058000A1 (en) | 2022-09-21 |
| MX2022005715A (es) | 2022-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022009018A2 (pt) | Biomarcadores para composições de nanopartícula | |
| Kolb et al. | Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program | |
| BR112019010020A2 (pt) | compostos com atividade anti-tumoral contra células cancerosas contendo mutações de egfr ou her2 exon 20 | |
| BR112012024590A2 (pt) | métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos | |
| BR112014032346A2 (pt) | métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes | |
| CL2017003457A1 (es) | Metodos para tratar tumores solidos usando terapia de combinacion del inhibidor de nanoparticulas mtor. | |
| MX2014015346A (es) | Pirrolo- o pirazolopirimidinas covalentes reversibles utiles para el tratamiento del cancer y de enfermedades autoinmunitarias. | |
| DOP2019000020A (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| MX2012000424A (es) | L-asparaginasa pegilada. | |
| BR112016029846A2 (pt) | ?composto, composição farmacêutica, métodos para o método para tratamento de um humano, para inibição da atividade de um polipeptídio de fosfatidilinositol 3-quinase e inibição excessiva ou reações imunes destrutivas ou crescimento ou uma proliferação de células de câncer, kit, e, uso de um composto, um sal farmaceuticamente aceitável, isômero, ou uma mistura do mesmo? | |
| BR112017026292A2 (pt) | muteína de lipocalina, molécula de ácido nucleico, vetor de expressão, célula hospedeira, método de produção de muteína de lipocalina, métodos de ligação de lag-3 em pacientes, de estímulo da reação imunológica em pacientes, de indução da proliferação de linfócitos t, de interferir com a ligação de lag-3 humano e de detecção da presença de lag-3, composição farmacêutica, imunoconjugado, uso de muteína e kit analítico ou de diagnóstico | |
| BR112014029851A2 (pt) | composto, inibidores da atividade da enzima ros1 quinase e da enzima ntrk quinase, composição farmacêutica, agente antitumor, agente terapêutico para um tumor, método para tratamento de um tumor, e, agente para tratamento de um tumor | |
| CY1120536T1 (el) | Μεθοδος και συνθεσεις για τη θεραπευτικη αγωγη του καρκινου | |
| BRPI0409198A (pt) | derivados quinolin-2-ona para o tratamento de doenças de vias aéreas | |
| PH12015501486A1 (en) | Nanoparticle compositions of albumin and paclitaxel | |
| BRPI0607809A2 (pt) | uso de uma composição compreendendo nanopartìculas, composição e kit | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| MX2017006942A (es) | Nuevos derivados de ester fosforamidato 3'-desoxiadenosina de 2' y/o 5' aminoacido como compuestos anti-cancer. | |
| BR112015032758A2 (pt) | nanopartículas poliméricas de docetaxel para o tratamento de câncer | |
| BR112022015792A2 (pt) | Inibidores de pad4 heterocíclicos | |
| MX2023001232A (es) | Medicamentos antiplaquetarios y usos de estos. | |
| BR112015029550A2 (pt) | Anticorpo anti-vegf e composição farmacêutica para prevenção, diagnóstico ou tratamento de câncer ou doença relacionada à angiogênese contendo o mesmo | |
| BR112023000654A2 (pt) | Composto de pirazolopirimidina usado como inibidor de atr quinase | |
| BR112014030113A2 (pt) | composição de catalisador, processo para a produção de álcoois ou olefinas, álcoois ou olefinas, e, complexo metálico | |
| BR112022007998A2 (pt) | Novo composto e composição farmacêutica para prevenção ou tratamento de câncer que compreende os mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |